Secondary Logo

Journal Logo

Erratum

Evaluation of the Waters MassTrak LC-MS/MS Assay for Tacrolimus and a Comparison to the Abbott Architect Immunoassay

Therapeutic Drug Monitoring: October 2016 - Volume 38 - Issue 5 - p 648
doi: 10.1097/FTD.0000000000000322
  • Free

Dear Editor,

There are errors that were placed by the editorial office in the manuscript “Evaluation of the Waters MassTrak LC-MS/MS Assay for Tacrolimus and a Comparison to the Abbott Architect Immunoassay” after our original submission. We did not catch these errors when reviewing the proofs. In the results sections, the following sentence is incorrect “The mean concentration (nanograms per milliliter) and coefficient of variation for low, mid, and high patient pools were 0.6% +/− 19.9%, 16.0 % ± 5.4 %, and 31.2% ± 5.8 %, respectively”. The correct sentence is “The mean concentration and coefficient of variation for the low, mid, and high patient pools were; 0.6 ng/mL ± 19.9 %, 16.0 ng/mL ± 5.4 %, and 31.2 ng/mL ± 5.8 %, respectively.” These errors occurred in the Abstract, Results section on page 300, in the Accuracy and Precision section on page 302 and in the Conclusions section on page 303.

Example of the error:

Thank you for correcting these errors.

Alec Saitman, PhD, DABCC

Associate Director, Clinical Chemistry

Providence Regional Laboratories

4400 NE Halsey St. Building 3

Portland, OR 97213

Office: (503) 893-7662

REFERENCE

Saitman A, Metushi IG, Mason DS, Fitzgerald RL. Evaluation of the Waters MassTrak LC-MS/MS assay for tacrolimus and a comparison to the Abbott Architect immunoassay. Ther Drug Monit. 2016;38:300–304.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.